Neuland Laboratories Ltd Share Price Today - Neuland Laboratories Ltd Stock Price Live NSE/BSE

Neuland Laboratories Ltd

NSE: NEULANDLAB BSE: 524558

₹13030

(-1.30)%

Sun, 08 Feb 2026, 06:46 pm

MTF 5xInvest in Neuland Laboratories Ltd with 5x Leverage Buy with MTF

Market Cap167.25B

PE Ratio69.61

Dividend0.09

Health Technology

Pharmaceuticals: Major

24.5K

1 Day

0 (0%)

No Result Found

Summary

Market Cap
16725.24
Net Profit
260.11
P/B
10.22
Sector P/E
31.94
P/E
59.90
EV/EBITDA
36.84
Debt/Equity (Industry)
0.16
Interest Cover (Industry)
22.44
ROCE (Industry)
20.01
RONW (Industry)
16.77
ROE
14.84
ROCE
18.58
Debt/Equity
0.09
EPS (TTM)
152.61
Dividend Yield
0.09
Book Value
1262.09
Interest Cover
34.40

Analysis

all

Pros

Dividends paid are thoroughly covered by earnings (10.5x coverage).
Dividends after 3 years are expected to be thoroughly covered by earnings (15.9x coverage).
Cash flow for Neuland Laboratories is expected to increase by more than 50% in 2 years time.
Neuland Laboratories's earnings are expected to grow significantly at over 20% yearly.
Neuland Laboratories's earnings growth is expected to exceed the India market average.

Cons

Dividend payments have increased, but Neuland Laboratories only paid a dividend in the past 7 years.
Neuland Laboratories has been paying a dividend for less than 10 years and during this time payments have been volatile (annual drop of over 20%).
Neuland Laboratories's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
Neuland Laboratories's dividend is below the markets top 25% of dividend payers in India (3.08%).
Neuland Laboratories is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	32.63	32.64	32.68	32.68	32.68
FII	20.90	20.60	21.69	22.11	23.86
DII	14.71	13.54	11.57	10.97	9.08
Public	31.76	32.81	33.67	33.84	33.98
Government	0.00	0.40	0.40	0.40	0.40

Technical Analysis

RSI

38.84

MACD

-504.38

50 DMA

14920.70

200 DMA

14195.23

Support and Resistance

Type	R1	R2	R3	PP	S1	S2	S3
Classic	19815.33	16772.33	15011.67	13729.33	11968.67	10686.33	7643.33
Fibonacci	16772.33	15609.91	14891.76	13729.33	12566.91	11848.76	10686.33
Camarilla	14087.83	13808.88	13529.94	13729.33	12972.06	12693.12	12414.17

Pivots Level: Classic

+6086.00

19815.33

+3043.00

16772.33

+1282.33

15011.67

13729.33

Pivot Point

LTP: 13030

-1760.67

11968.67

-3043

10686.33

-6086

7643.33

Moving Average

SMAEMA

Period

Value

10-EMA
13281.89
20-EMA
13616.17
30-EMA
13979.40
50-EMA
14490.63
100-EMA
14797.09
200-EMA
14331.37

Announcement Date	Purpose	Action	Ex Date
09 Feb 2026	board-meetings	Quarterly Results
07 Nov 2025	board-meetings	Quarterly Results
15 May 2025	agm
15 May 2025	dividend	₹12.00 Dividend /Share	18 Jul 2025
10 May 2024	dividend	₹14.00 Dividend /Share	13 Jul 2024
10 May 2024	agm
11 May 2023	agm
11 May 2023	dividend	₹10.00 Dividend /Share	12 Jul 2023
17 Jun 2022	agm
10 May 2022	dividend	₹5.00 Dividend /Share	15 Jul 2022

Neuland Laboratories Ltd

Sun Pharmaceutical Industries Ltd

Cipla Ltd

Divis Laboratories Ltd

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd

About Neuland Laboratories Ltd

Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.

Industry

Pharmaceuticals - Indian - Bulk Drugs

Founded

1984

Headquarters

CEO

D Saharsh Rao

Employees

Contact

Website

http://www.neulandlabs.com

ir@neulandlabs.com

Phone

91-40-30211600

Location

11 Th Floor Phoenix IVY Buildi, Plot No 573A-III Road No 82, Hyderabad, Telangana, 500035

Year	History
2012	Neuland Laboratories Ltd issued rights in the ratio of 5:12. The registered office of the company was shifted to Sanali Info park, 'A' Block, Ground floor,8-2-120/113, Road No.2, Banajara Hills, Hyderabad- 500034.
2013	The board recommended a dividend of Rs. 1.20 per share of a face value of Rs. 10 each. Neuland Labs received the 2013 CMO Leadership Award for Regulatory Excellence.
2014	Neuland Labs inaugurated a new manufacturing facility constructed for its collaboration with Mitsubishi Healthcare Unit API Corporation. The board recommended a dividend of 30% at Rs. 3 per equity share on a face value of Rs. 10 each. Neuland Laboratories announced rights in the ratio of 4:25.
2016	The company entered into a Joint Development Agreement with Phoenix Embassy Techno Zone Private Limited.
2017	Neuland Labs completed the acquisition of an API plant.

Client Name	Order Side	QTY	Avg Price	Date
SMALLCAP WORLD FUND INC	Sell	484434	15618.16	12 Dec 2024

neuland laboratories ltd. News

Neuland Labs Board Meet Set for Feb 9 to Review Q3 Results

Neuland Laboratories has scheduled a board meeting on February 9, 2026, to approve Q3FY26 unaudited financial results. Trading window remains closed until 48 hours post-declaration.

21 Jan 2026

co actions results

Neuland Labs Exports Surge 143% MoM to $20.4M

Neuland Laboratories reported a significant 143% month-on-month increase in exports, reaching $20.4 million, demonstrating strong international business growth and operational momentum.

13 Jan 2026

stocks

Neuland Laboratories Approves 1.89 Billion Rupees Investment for New R&D Center

Neuland Laboratories has approved an investment of 1.89 billion rupees for establishing a new research and development center. This significant capital allocation demonstrates the pharmaceutical company's commitment to expanding its R&D capabilities and strengthening its innovation infrastructure.

30 Nov 2025

stock

Neuland Laboratories Approves ₹1.89 Billion Investment for New R&D Center

Neuland Laboratories has approved an investment of ₹1.89 billion for establishing a new research and development center. This significant capital allocation demonstrates the company's commitment to expanding its R&D capabilities and strengthening its pharmaceutical development infrastructure.

28 Nov 2025

stock

Neuland Laboratories Reports Record Revenue of Rs 516 Crore in Q2, Up 63.7% Year-on-Year

Neuland Laboratories achieved its highest quarterly revenue of Rs 516 crore in Q2, representing a 63.7% increase from Rs 315 crore in the same period last year. The growth was primarily driven by commercial CMS (Contract Manufacturing Services) projects, with the company's top two commercial CMS molecules performing well. EBITDA stood at Rs 156.9 crore with a margin of 30.4%, while profit after tax reached Rs 96.5 crore compared to Rs 32 crore in Q2 of the previous year. EPS for the quarter was Rs 75.18 per share. The company expects commercialization of another molecule this year and reported strong customer interest in its peptide capabilities. Working capital increased to 155 days of sales due to higher inventories and receivables. CAPEX for the quarter was Rs 91 crore, with Rs 170.7 crore invested in the six-month period. The company's peptide facility investment is progressing as planned, with Module-1 expected to be operational in the next financial year.

12 Nov 2025

earnings

Showing 1–5 of 46

Rows per page:

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800